Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Famotidine

FDA-approved product (tablet, oral), marketed as Famotidine, Famotidine Preservative Free, Famotidine Preservative Free (Pharmacy Bulk) and 7 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famotidine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chest pain
  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Peptic ulcer
  • Rheumatoid arthritis
  • Ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
H2-receptor antagonists
FDA pharmacologic class
Histamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Famotidine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famotidine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Efficacy in Treatment of Facial Melasma Combined With Thulium 1927-nm Fractional Laser and Topical H2R Antagonist

    NCT06313307 · start 2023-04-01

    Registered record
    Registry ID
    NCT06313307
    Conditions
    Melasma
    Interventions
    topical H2R antagonist; Thulium 1927-nm Fractional Laser
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-01
    Completion
    2023-11-25
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelasma
    Interventiontopical H2R antagonist; Thulium 1927-nm Fractional Laser
    PhaseNot applicable
    Registry statusCompleted

  • Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

    NCT05085574 · start 2023-02-07

    Registered record
    Registry ID
    NCT05085574
    Conditions
    2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection; COVID-19 Pandemic; COVID-19 Virus Disease; COVID-19 Virus Infection; Covid19; Coronavirus Disease 2019; SARS-CoV-2 Infection; SARS-CoV-2 Acute Respiratory Disease; COVID-19
    Interventions
    Famotidine; Celecoxib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-02-07
    Completion
    2023-02-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection +8 more
    InterventionFamotidine; Celecoxib; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

    NCT05255276 · start 2022-02-02

    Registered record
    Registry ID
    NCT05255276
    Conditions
    Healthy Adults
    Interventions
    Sitravatinib 50 mg; Sitravatinib 100 mg; Itraconazole; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-02-02
    Completion
    2023-02-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionSitravatinib 50 mg; Sitravatinib 100 mg; Itraconazole; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

    NCT05077332 · start 2021-12-29

    Registered record
    Registry ID
    NCT05077332
    Conditions
    2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection; COVID-19 Pandemic; COVID-19 Virus Disease; COVID-19 Virus Infection; Covid19; Coronavirus Disease 2019; SARS-CoV-2 Infection; SARS-CoV-2 Acute Respiratory Disease; COVID-19
    Interventions
    Famotidine; Celecoxib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-29
    Completion
    2025-11-10
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection +8 more
    InterventionFamotidine; Celecoxib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

    NCT04862585 · start 2021-10-07

    Registered record
    Registry ID
    NCT04862585
    Conditions
    Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Pro
    Interventions
    Cimetidine; Dexamethasone; Diphenhydramine; Famotidine; Paclitaxel; Quality-of-Life Assessment; Ranitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-10-07
    Completion
    2024-06-21
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8 +21 more
    InterventionCimetidine; Dexamethasone; Diphenhydramine; Famotidine +3 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Explore the Effect of Acid-reducing Agents

    NCT04935112 · start 2021-07-07

    Registered record
    Registry ID
    NCT04935112
    Conditions
    Healthy Adults
    Interventions
    Sitravatinib; Pantoprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-07
    Completion
    2022-07-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionSitravatinib; Pantoprazole; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

    NCT04903093 · start 2021-06-04

    Registered record
    Registry ID
    NCT04903093
    Conditions
    Healthy Volunteers
    Interventions
    Abrocitinib tablet; Abrocitinib Suspension F1; Abrocitinib Suspension F2; Abrocitinib Suspension F3; Abrocitinib Suspension F4; Abrocitinib Suspension F5; Abrocitinib Suspension F6; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-04
    Completion
    2021-10-26
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAbrocitinib tablet; Abrocitinib Suspension F1; Abrocitinib Suspension F2; Abrocitinib Suspension F3 +4 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

    NCT04834752 · start 2021-05-01

    Registered record
    Registry ID
    NCT04834752
    Conditions
    COVID-19
    Interventions
    No intervention (Retrospective Cohort Observational)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-05-01
    Completion
    2021-12-31
    Enrolment
    400,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNo intervention (Retrospective Cohort Observational)
    PhaseNot recorded
    Registry statusCompleted

  • An Outpatient Study Investigating Non-prescription Treatments for COVID-19

    NCT04621149 · start 2020-11-15

    Registered record
    Registry ID
    NCT04621149
    Conditions
    COVID-19
    Interventions
    chlorine dioxide; zinc acetate; Famotidine; placebo; lactoferrin, green tea extract
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-15
    Completion
    2022-03-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    Interventionchlorine dioxide; zinc acetate; Famotidine; placebo +1 more
    PhasePhase 2
    Registry statusTerminated

  • I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    NCT04488081 · start 2020-07-31

    Registered record
    Registry ID
    NCT04488081
    Conditions
    COVID-19
    Interventions
    Remdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc; Icatibant; Apremilast; dornase alfa; Celecoxib; Famotidine; IC14; Aviptadil; narsoplimab; Cyproheptadine; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-31
    Completion
    2030-07-31
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionRemdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc +10 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

    NCT04453189 · start 2020-07-20

    Registered record
    Registry ID
    NCT04453189
    Conditions
    Healthy Participants
    Interventions
    JNJ-64417184; Lansoprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-20
    Completion
    2020-09-14
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionJNJ-64417184; Lansoprazole; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

    NCT04470778 · start 2020-07-20

    Registered record
    Registry ID
    NCT04470778
    Conditions
    Healthy Participants
    Interventions
    BMS-986256; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-20
    Completion
    2021-03-28
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986256; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • Tongjiang Series Prescription Combined With PPIs Descending Ladder Withdrawal in Treating Nonerosive Reflux Disease

    NCT04340297 · start 2020-06-15

    Registered record
    Registry ID
    NCT04340297
    Conditions
    Nonerosive Reflux Disease
    Interventions
    Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules); Acid inhibitors; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-06-15
    Completion
    2021-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonerosive Reflux Disease
    InterventionTongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules); Acid inhibitors; Placebo
    PhasePhase 3
    Registry statusUnknown

  • A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

    NCT04209699 · start 2019-12-27

    Registered record
    Registry ID
    NCT04209699
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-27
    Completion
    2020-02-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • BE Study of Gaster®D Tab 20mg (Manufacturer Changed)

    NCT04123899 · start 2019-10-11

    Registered record
    Registry ID
    NCT04123899
    Conditions
    Gastroduodenal Ulcer
    Interventions
    IGAD→GSTD; GSTD→IGAD
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-10-11
    Completion
    2020-01-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroduodenal Ulcer
    InterventionIGAD→GSTD; GSTD→IGAD
    PhaseNot applicable
    Registry statusUnknown